Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Current Deferred Revenue (2019 - 2024)

Historic Current Deferred Revenue for Apyx Medical (APYX) over the last 6 years, with Q4 2024 value amounting to $2.0 million.

  • Apyx Medical's Current Deferred Revenue rose 1764.71% to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.0 million, marking a year-over-year increase of 1764.71%. This contributed to the annual value of $2.0 million for FY2024, which is 1764.71% up from last year.
  • Apyx Medical's Current Deferred Revenue amounted to $2.0 million in Q4 2024, which was up 1764.71% from $1.7 million recorded in Q4 2023.
  • Apyx Medical's Current Deferred Revenue's 5-year high stood at $2.3 million during Q4 2022, with a 5-year trough of $600000.0 in Q4 2020.
  • In the last 5 years, Apyx Medical's Current Deferred Revenue had a median value of $1.9 million in 2021 and averaged $1.7 million.
  • As far as peak fluctuations go, Apyx Medical's Current Deferred Revenue surged by 21666.67% in 2021, and later crashed by 2608.7% in 2023.
  • Over the past 5 years, Apyx Medical's Current Deferred Revenue (Quarter) stood at $600000.0 in 2020, then skyrocketed by 216.67% to $1.9 million in 2021, then increased by 21.05% to $2.3 million in 2022, then fell by 26.09% to $1.7 million in 2023, then rose by 17.65% to $2.0 million in 2024.
  • Its last three reported values are $2.0 million in Q4 2024, $1.7 million for Q4 2023, and $2.3 million during Q4 2022.